header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FIG-150506-24
Sasore et al., 2014 - Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo. PLoS One   9:e105280 Full text @ PLoS One
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Gene:
Fish:
Condition:
Anatomical Terms:
Stage: Prim-5
PHENOTYPE:
Fish:
Condition:
Observed In:
Stage: Prim-5

Fig. 3

PI3K/Akt/mTOR inhibitors inhibit developmental angiogenesis of the intersegmental vasculature.

Representative images demonstrating anti-angiogenic effects of PI3K/Akt/mTOR inhibitors on ISV development. In 0.1% DMSO-treated control larvae ~25 ISVs pairs develop (A) and high magnification (B). 5 µM NVP-BEZ235 + PI-103 (C), 5 µM LY294002 + NVP-BEZ235 (D) and 10 µM NVP-BEZ235 (E) exhibited significant anti-angiogenic effects compared to individual drugs at 5 µM (F-H). White arrows indicate the ISVs sprouting from the dorsal aorta (DA) to the dorsal longitudinal anastomic vessel (DLAV). Scale bar in A is 500 µm and in B is 100 µm (B). n = 25-30.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
EGFP y1Tg control Prim-5 dorsal aorta IFL
Prim-5 intersegmental vessel IFL
Prim-5 vasculature IFL
y1Tg chemical treatment: pharmaceutical Prim-5 dorsal aorta IFL
Prim-5 intersegmental vessel IFL
Prim-5 vasculature IFL
y1Tg chemical treatment: pharmaceutical Prim-5 dorsal aorta IFL
Prim-5 intersegmental vessel IFL
Prim-5 vasculature IFL
y1Tg chemical treatment: pharmaceutical Prim-5 dorsal aorta IFL
Prim-5 intersegmental vessel IFL
Prim-5 vasculature IFL
y1Tg chemical treatment: pharmaceutical Prim-5 dorsal aorta IFL
Prim-5 intersegmental vessel IFL
Prim-5 vasculature IFL
y1Tg chemical treatment: pharmaceutical Prim-5 dorsal aorta IFL
Prim-5 intersegmental vessel IFL
Prim-5 vasculature IFL
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
y1Tg chemical treatment: pharmaceutical Prim-5 intersegmental vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Prim-5 intersegmental vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Prim-5 intersegmental vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Prim-5 intersegmental vessel sprouting angiogenesis decreased process quality, abnormal
y1Tg chemical treatment: pharmaceutical Prim-5 intersegmental vessel sprouting angiogenesis decreased process quality, abnormal
Acknowledgments:
ZFIN wishes to thank the journal PLoS One for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ PLoS One